Cingulate Inc (CING) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cingulate Inc (CING) has a cash flow conversion efficiency ratio of -1.434x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.60 Million) by net assets ($2.51 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Cingulate Inc for the company's overall valuation and market capitalisation.
Cingulate Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Cingulate Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cingulate Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cingulate Inc ranked by their cash flow conversion efficiency. Explore Cingulate Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Seouleaguer Co. Ltd
KQ:043710
|
0.033x |
|
Grupo Greening 2022 SA
MC:GGR
|
N/A |
|
Arn Media Ltd
AU:A1N
|
0.141x |
|
Brimstone Investment Corporation Limited
JSE:BRN
|
0.041x |
|
Lark Distilling Co. Ltd
AU:LRK
|
-0.021x |
|
ZK International Group Co Ltd
NASDAQ:ZKIN
|
0.032x |
|
Montebalito S.A.
MC:MTB
|
-0.075x |
|
Triller Group Inc.
NASDAQ:ILLR
|
0.024x |
Annual Cash Flow Conversion Efficiency for Cingulate Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Cingulate Inc from 2019 to 2025. View latest Cingulate Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.51 Million | $-17.25 Million | -6.874x | -177.73% |
| 2024-12-31 | $7.46 Million | $-18.45 Million | -2.475x | -213.08% |
| 2023-12-31 | $-6.87 Million | $-15.03 Million | 2.189x | +153.49% |
| 2022-12-31 | $3.88 Million | $-15.88 Million | -4.091x | -717.41% |
| 2021-12-31 | $20.84 Million | $-10.43 Million | -0.501x | +90.50% |
| 2020-12-31 | $1.29 Million | $-6.81 Million | -5.270x | +65.95% |
| 2019-12-31 | $615.88K | $-9.53 Million | -15.478x | -- |
About Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It … Read more